NNVCNanoViricides, Inc.
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Older | ||
 NanoViricides closes $2M direct offering NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses. The clinical-stage antiviral drug developer sold about 1.3 million shares of common stock, or pre-funded warrants in... | ||
 NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-387 could be effective against the Bundibugyo strain of Ebola virus that has prompted the World Health Organisation to declare a global health emergency. The WHO designated the outbreak in... | ||
 NanoViricides to raise $2M in registered direct offering NanoViricides (NYSE-A:NNVC) said it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approximately $2 million in a registered direct offering. Under the terms of the agreement, the company will sell just over 1.3 million common... | ||
 Hantavirus Outbreak Shows Need for Broad-Spectrum Antiviral Drugs By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the recent outbreak of the hantavirus on a cruise ship highlights the need for broad-spectrum antiviral drugs such as NV-387. The hantavirus gets into the lungs through droplets of cough or spit from an infected person and incidents are becoming more common on cruises, making a global […] | EExec Edge | |
 NanoViricides says Phase I antiviral drug could address gap exposed by hantavirus cruise ship outbreak NanoViricides (NYSE-A:NNVC) is pointing to its lead drug candidate NV-387 as a potential solution to a critical gap in infectious disease preparedness, as a deadly hantavirus outbreak aboard a cruise ship triggers a costly global containment effort. The Connecticut-based clinical-stage... | ||
 NanoViricides to Participate at D. Boral Capital Global Conference in NYC By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said it will participate at the D. Boral Capital Global Conference, to be held on May 7, 2026, at The Plaza Hotel in New York City. The company’s President and Executive Chairman, Anil R. Diwan, PhD, will offer one-on-one meetings on the same day from 9:45AM to 2:45PM ET. […] | EExec Edge | |
 NanoViricides (NNVC) Secures FDA Orphan Drug Status for NV-387 Measles Treatment NanoViricides, Inc. (NYSEAmerican:NNVC) said its antiviral candidate NV-387 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of measles, marking a regulatory milestone as the company advances its clinical-stage pipeline. The designation, awarded by the FDA’s Office of Orphan Products Development, provides incentives including tax credits for qualifying […] | IInsider Monkey | |
 NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA By Karen Roman NanoViricides, Inc. (NYSE: NNVC) said the FDA granted “Orphan Drug Designation” (ODD) to its clinical-stage, antiviral drug NV-387 for the treatment of measles, giving the company seven years of market exclusivity after approval and access to tax credits, among other benefits. There is no approved drug to treat the disease and NV-387 […] | EExec Edge | |